.Attribute Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ sophisticated breast cancer and also active or even secure brain metastases showed consistent intracranial activity and also wide spread effectiveness of T-DXd.